Vermillion Corporation

Leland Stanford Junior University

Johns Hopkins University

The University of Texas System

Ciphergen Biosystems, Inc.

Other

Ajinomoto Co., Ltd.

University of Kentucky Research Foundation

Affymetrix, Inc.

Biosite Incorporated

Vermilllion, Inc.

Aspira Women's Health Inc.

Bio-rad Laboratories, Inc.

Eric Thomas Fung

John P Cooke

Zhen Zhang

Daniel W Chan

Fujun Zhang

Xiao-Ying Meng

Tai-Tung Yip

Eiichiro Kimura

Michael H Shapero

Ronald J Sapolsky

Robert C Bast

Vladimir Podust

William E Rich

Edward J Gavin

Jeanette Pruzan Schmidt

Leonid Braginsky

Anju Shukla

Monica Chadha

Chris D Paulse

Zheng Wang

Kenneth Francis Buechler

Jin Song

Andre T Baron

Jiang Li

Orna Mizrahi Man

Bjorg Kristjansdottir

Karin Sundfeldt

Andrew Wilson

Carolyn N White

Jinong Li

Elichiro Kimura

Frederick R Ueland

J R Van Nagell

Paul D Depriest

Charlotte Clarke

Valdimir Podust

Mats Brannstrom

Robert Bast

Kevin Coombes

Paul Duane Depriest

Andre Thomas Baron

Jr Van Nagell

Frederick Rand Ueland

Van Nagell, Jr

Enrique Dalmasso

This disclosure provides methods and systems useful in array-based analysis of mixed nucleic acid populations, including for multiplex genotyping of a mixed nucleic acid sample and for detecting differences in copy number of a target polynucleotide and/or a target chromosome (e.g., microdeletions, duplications and aneuploidies). The disclosure also provides methods and systems useful in the diagnosis of genetic abnormalities in a mixed nucleic acid population taken non-invasively from an organism, such as a sample of blood, plasma, serum, urine stool or saliva. The disclosed methods and systems find use in multiple applications, including prenatal testing and cancer diagnostics. The disclosure is based on the hybridisation of amplified fragments from the sample, e.g. a maternal sample, which may employ molecular inversion probes MIP to an oligonucleotide array and the detection of the alleles based on different signals from the different alleles of the SNP. The disclosure also discloses how the determination of the allele ratio may be used in the determination of fetal and maternal CNVs, e.g. aneuploidies.

Array-based methods for analysing mixed samples using differently labelled allele-specific probes

This disclosure provides methods and kits useful in analysis of mixed nucleic acid populations, including for multiplex genotyping of a mixed nucleic acid sample and for detecting differences in copy number of a target polynucleotide and/or a target chromosome (e.g., microdeletions, duplications and aneuploidies). The disclosure also provides methods and systems useful in the diagnosis of genetic abnormalities in a mixed nucleic acid population taken non-invasively from an organism, such as a sample of blood, plasma, serum, urine stool or saliva. The disclosed methods and systems find use in multiple applications, including prenatal testing and cancer diagnostics. The method is based on the hybridisation of amplified fragments obtained from the sample, e.g. using molecular inversion probes (MIP) to an oligonucleotide array and the detection of the alleles based on different signals from the different alleles of the SNP.

The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry.

Biomarkers for ovarian cancer CTAP3-related proteins

Biomarker for ovarian cancer CTAP3-related proteins

The present invention provides &#x3b2;2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.

&#x3b2;-2 microglobulin as a biomarker for peripheral artery disease

The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

Biomarkers for ovarian cancer

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry.

Beta-2 microglobulin as a biomarker for peripheral artery disease

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, it has been found that the biomarkers set forth in Table 1 are biomarkers for ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry, immunoassay, or other means.

Methods for diagnosing ovarian cancer

This invention provides biomarkers whose concentrations in blood plasma are associated with the presence or absence of PAD in the patient from whom the plasma sample is taken. The invention also provides biomarkers for distinguishing between PAD patients who are long claudicators and PAD patients who are not. In addition, the invention provides methods for identifying additional biomarkers, methods for detecting the biomarkers in patients, and methods for identifying agents, including pharmaceutical agents, which interact with the biomarkers and are useful for preventing or treating PAD in patients.

Biomarkers for peripheral artery disease

The invention provides biomarkers including &#x3b2;-2-microglobulin, Cystatin C, hsCRP and glucose as well as methods for using the biomarkers for diagnosing and/or assessing the risk of peripheral artery disease in a subject. In some embodiments, the subject being tested may be suffering from or at risk of other circulatory diseases, including coronary artery disease. Hemoglobin A1c or other proxies for measuring glucose levels may be substituted for or measured in addition to glucose in the context of the present invention.

Panel of biomarkers for peripheral arterial disease

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry.

Biomarkers for breast cancer

Growing community of inventors

Los Altos, CA, United States of America

Eric Thomas Fung